home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Patient Centricity in Developing Strategies for Trial Execution

 
  July 16, 2013  
     
 
Hyatt Regency Bethesda, Bethesda, MD
October 21-22, 2013


Some of the biggest challenges of delivering a successful clinical study are identifying, measuring and understanding the flow of a per protocol patient segment as it exists in the real world. This is important for selecting both the number and kind of clinical sites needed to deliver the required number of patients at the agreed recruitment rate. Understanding patient segmentation helps shape and informs your patient recruitment and retention strategy. Developing this strategy with the patient at the center is key to a successful clinical study. Patient centricity in clinical trials is at the forefront of clinical research excellence and innovation today, allowing companies to better leverage online communities, telemedicine, mHealth, EMRs and virtual trials to increase clinical trial efficiency. This conference covers how the characterization of patient segments, data-driven site selection, optimized feasibility assessment and implementation of patient-centric trial planning are improving cycle time predictability and efficient execution.

Presentations: 

Day 1:

  • Patient Centricity: The Most BASIC and LEAST APPLIED Clinical Research Concept
  • What Does Patient Centricity Mean to Patients?
  • The Feasibility Assessment: New Tools and Methodology to Support Your Assessment
  • Let’s Jam: Feasibility and Country Allocation
  • Co-Presentation: Establishing a Culture of Clinical Research in a Chronic Disease Patient Population
Day 2:
  • Using a Data-Driven Approach with Sites during the Feasibility Process to Help Ensure a More Accurate and Successful Trial Outcome
  • Mapping Chronic Disease for Efficient Identification of Clinical Trial Outpost Development
  • Advancing Patient Recruitment and Retention through Patient-Controlled Medical Records
  • Optimizing Social Media in Clinical Research
  • Co-Presentation: Patient Centricity in Developing Strategies for Trial Design and Execution
  • Why the Evolution of Site Evaluation/Selection Has Been Counterproductive, and How Industry Must Adapt
  • Alternative Approaches and New Collaborative Models for the Pharma Industry to Improve the Quality of Clinical Studies and Bring New Medicines to Patients Faster
  • Aligning Strategy and Operations to Accelerate Drug Development
 
 
Organized by: Cambridge Healthtech Institute (CHI)
Invited Speakers:
  • Marisa Co, President, National Research Institute; former Executive Director, R&D Finance, Amgen
  • Jane Perlmutter, Ph.D., MBA, President and Founder, Gemini Group; Steering Committee Member, Clinical Trials Transformation Initiative (CTTI)
  • Sameer Tandon, Group Head, Outsourcing, Sourcing, Novartis Pharmaceuticals Corporation
  • Jackie Kent, Director, Clinical Development Information & Optimization (CDIO), Eli Lilly and Company
  • Jill VanDalfsen, Director of Operations, Therapeutics Development Network Coordinating Center (TDNCC)
  • Cindy George, Director, Clinical Research Resources, Cystic Fibrosis Foundation
  • Christopher Dowd, Clinical Research Program Manager, Cystic Fibrosis Foundation
  • Nicole Burgeson, Site Director, RxTrials
  • Les Jebson, Director, University of Florida - Pathology, University of Florida Academic Health Center
  • David Beyer, Vice President, Patients Know Best
  • Stella Stergiopoulos, Project Manager, Tufts Center for the Study of Drug Development, Tufts University School of Medicine
  • Bill Gwinn, MBA, Vice President, Clinical Informatics Solutions, OptumInsight
  • Christine Dehner, Senior Clinical Trial Manager, Clinical Ops, Seattle Genetics, Inc.
  • Marta Fields, Director, Compliance and Quality Systems, Seattle Genetics, Inc.
  • Adam Chasse, COO, RxTrials
  • Robin DeMent, Vice President, R&D-IT, Medicines Development Capabilities, GlaxoSmithKline
  • Tania Bojanowski, Director, Development Operations & Strategic Planning, sanofi oncology
 
Deadline for Abstracts: ---
 
Registration: Register Now
E-mail: kwaterman@healthtech.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.